14.4% rise in Humacyte's short interest in September, with 16.03 million shares sold short.

Humacyte, Inc. (NASDAQ: HUMA) experienced a 14.4% rise in short interest in September, totaling 16.03 million shares, with a short-interest ratio of 5.1 days. Currently, 16.4% of its shares are sold short. Brokerages have mostly assigned positive ratings, with a $15 price target from Benchmark. CEO Laura E. Niklason sold 157,704 shares at $5.42 each. Institutional investors hold 44.71% of Humacyte, which has a market cap of $691.88 million.

October 17, 2024
3 Articles